---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-111405"
form_type: "8-K"
ticker: "PRGO"
cik: "0001585364"
company_name: "PERRIGO Co plc"
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:58:37.176251+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perrigo to sell HRA Pharma Rare Diseases to Esteve for up to €275M

## Summary
- Total consideration up to €275M: €190M cash plus up to €85M earnout on sales milestones.
- Esteve Healthcare signed binding offer; Perrigo has a put option to finalize sale.
- Transaction expected to close in Q3 2024, subject to Works Council consultation and regulatory approvals.
- Sale includes HRA Pharma Rare Diseases business; Perrigo will proceed after French Works Council process.

## SEC filing metadata
- accession: 0001193125-24-111405
- form_type: 8-K
- ticker: PRGO
- cik: 0001585364
- company_name: PERRIGO Co plc
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585364/000119312524111405/0001193125-24-111405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585364/000119312524111405/d813932d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-111405
- JSON: https://secwatch.observer/filing/0001193125-24-111405.json
- Plain text: https://secwatch.observer/filing/0001193125-24-111405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.